We hypothesized that IFN-γ released by tumor antigen-specific CD8+ T cells, either endogenous or vaccine-mediated, would upregulate PD-L1 expression on tumor cells, increasing their sensitivity to avelumab-mediated ADCC (Figure 3A). This evidence concerns the gene IFNG and neoplasm.